RA Capital Management is a multi-stage investment manager dedicated to evidence-based, science-led investing in public and private healthcare, life sciences, and planetary health companies. Founded in 2004 and based in Boston, the firm supports companies from NewCo creation through IPO and public markets.
49% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $109.8M (across 415 rounds with reported amounts).
Portfolio
309
Fund Size
$880M
Top Stage
Series B
Last 12 Mo
37
Team
Peter Kolchinsky, PhD
Managing Partner
Rajeev Shah
Managing Partner
Emily Minkow, MBA
Managing Director, Venture
Nandita Shangari, PhD
Managing Director, Venture
Renny Gleeson
Managing Director, Marketing
Adrian Bot, MD, PhD
Venture Partner
Alden Masters
Human Resources Business Partner
Anish Suri, PhD
Consulting Venture Partner
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 ILiAD Biotechnologies | Series B | $115M | Sep 2026 |
| AAlpha-9 | Series C | $175M | Sep 2026 |
 Aiolos | Series A | $245M | Sep 2026 |
| CCorxel | Series D | $287M | Sep 2026 |
| LLifeMine | Series D | $75M | Sep 2026 |
| LLifeMine | Series E | $188M | Sep 2026 |
| PParabilis | Series F | $305M | Sep 2026 |
 Ambros Therapeutics | Series A | $125M | Aug 2026 |
| LLifeMine | Series E | $188M | Aug 2026 |
 Nava Therapeutics | Unknown | $89M | Jul 2026 |
| OOllin | Series B | $330M | Jun 2026 |
 cAMPfield Therapeutics | Series A | $180M | Jun 2026 |
| CcAMPfield | Series A | $180M | Jun 2026 |
 Solstice | Series A | $21M | May 2026 |
 CellCentric | Series D | $220M | May 2026 |
 Terremoto Biosciences | Series C | $108M | Apr 2026 |
 Adcendo ApS | Series C | $75M | Apr 2026 |
 Incyclix Bio | Series B | $5M | Apr 2026 |
 Stipple Bio | Series A | $100M | Apr 2026 |
 Pinnacle Medicines | Series B | $89M | Mar 2026 |
 Ovid Therapeutics Inc. | Unknown | $60M | Mar 2026 |
| AAtavistik | Series B | — | Mar 2026 |
 Slate Medicines | Series A | $130M | Feb 2026 |
| ILiAD Biotechnologies | Series B | $115M | Feb 2026 |
 Avalanche | Series A | $29M | Feb 2026 |
Top Co-Investors
Last updated: 7 October 2026